Committed to Patients. Driven to Discover.

At Bristol Myers Squibb, we are driven by the discovery of science that may transform the
lives of cancer patients.

Until we can meet again, please explore our oncology and hematology pipeline below.

Solid Tumor and Hematology Pipeline

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that investigational agents or investigational uses will receive health authority approval or become commercially available in any country. Information as of September 2020.

Filter by Therapeutic Area and Phase Clear All
Advanced Solid Tumors
Nivolumab ± relatlimab
Modality:
Anti–PD-1 ± anti–LAG-3
Area of Research:
Advanced solid tumors
Phase: 3
Nivolumab ± linrodostat mesylate
Modality:
Anti–PD-1 ± IDO1 inhibitor
Area of Research:
Advanced solid tumors
Phase: 3
Nivolumab ± bempegaldesleukin (NKTR-214)
Modality:
Anti–PD-1 ± CD122-preferential IL-2 pathway agonist
Area of Research:
Advanced solid tumors
Phase: 3
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
TMB-H advanced or metastatic solid tumors
Phase: 2
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
Advanced or metastatic solid tumors
Phase: 1/2
Nivolumab + ipilimumab + MEK inhibitor
Modality:
Anti–PD-1 ± anti–CTLA-4 + MEK inhibitor
Area of Research:
Advanced or metastatic solid tumors
Phase: 1/2
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
Virus-associated tumors
Phase: 1/2
Nivolumab + anti-CD38
Modality:
Anti–PD-1 + anti-CD38
Area of Research:
Virus-associated tumors
Phase: 1/2
Nivolumab ± hyaluronidase*
Modality:
Anti–PD-1 ± hyaluronidase
Area of Research:
Advanced or metastatic solid tumors
Phase: 1/2
Nivolumab + ipilimumab + hyaluronidase*
Modality:
Anti–PD-1 + anti–CTLA-4 + hyaluronidase
Area of Research:
Advanced solid tumors
Phase: 1/2
Ipilimumab ± hyaluronidase*
Modality:
Anti–CTLA-4 ± hyaluronidase
Area of Research:
Advanced solid tumors
Phase: 1/2
Modality:
CCR2/CCR5 inhibitor
Area of Research:
Advanced solid tumors
Phase: 1/2
Modality:
Anti–CTLA-4–NF ± anti–PD-1
Area of Research:
Advanced solid tumors
Phase: 1/2
Modality:
Anti–CTLA-4 Probody
Area of Research:
Advanced solid tumors
Phase: 1/2
Modality:
Anti–TIM-3
Area of Research:
Advanced solid tumors
Phase: 1/2
Modality:
Anti-TIGIT
Area of Research:
Advanced solid tumors
Phase: 1/2
Modality:
Anti-CD73
Area of Research:
Advanced solid tumors
Phase: 1/2
Modality:
BET (BRD4) inhibitor
Area of Research:
Advanced solid tumors
Phase: 1/2
Modality:
Anti–IL-8
Area of Research:
Advanced solid tumors
Phase: 1/2
Modality:
Anti–CTLA-4–NF Probody™
Area of Research:
Advanced solid tumors
Phase: 1/2
Relatlimab
Modality:
Anti–LAG-3
Area of Research:
Advanced solid tumors
Phase: 1
Modality:
NLRP3 agonist
Area of Research:
Advanced solid tumors
Phase: 1
Modality:
STING agonist
Area of Research:
Advanced solid tumors
Phase: 1
CC-90010
Modality:
BET inhibitor
Area of Research:
Solid tumors
Phase: 1
CC-95251
Modality:
Anti-SIRPα
Area of Research:
Solid tumors
Phase: 1
CD3xPSCA Bispecific (GEMoaB)
Modality:
CD3xPSCA bispecific antibody
Area of Research:
Solid tumors
Phase: 1
IK175
Modality:
AHR antagonist
Area of Research:
Solid tumors
Phase: 1
Modality:
Anti-NKG2A ± anti–PD-1
Area of Research:
Advanced solid tumors
Phase: 1/2
AG-270 ± chemo
Modality:
Anti-MAT2A
Area of Research:
Advanced solid tumors with homozygous deletion of MTAP
Phase: 1
Azacitidine
Modality:
Oral HMA
Area of Research:
Solid tumors
Phase: 2
CC-90011
Modality:
LSD1 inhibitor
Area of Research:
Advanced solid tumors
Phase: 2
CC-95775
Modality:
BET inhibitor
Area of Research:
Advanced solid tumors
Phase: 1
Expand all Displaying 5 of 31

No results found. Try adjusting filters to view more results.

Breast
Nivolumab + CDK inhibitor + aromatase inhibitor
Modality:
Anti–PD-1 + CDK inhibitor + aromatase inhibitor
Area of Research:
Neoadjuvant ER+/HER2- breast cancer
Phase: 2
CDK inhibitor + aromatase inhibitor followed by nivolumab + CDK inhibitor + aromatase inhibitor
Modality:
CDK inhibitor + aromatase inhibitor followed by anti–PD-1 + CDK inhibitor + aromatase inhibitor
Area of Research:
Neoadjuvant ER+/HER2- breast cancer
Phase: 2
Nivolumab + chemo followed by nivolumab + endocrine therapy
Modality:
Anti–PD-1
Area of Research:
Neoadjuvant/adjuvant high-risk breast cancer
Phase: 3

No results found. Try adjusting filters to view more results.

Central Nervous System
Nivolumab + chemo + RT
Modality:
Anti–PD-1
Area of Research:
1L MGMT methylated GBM
Phase: 3
Nivolumab + RT
Modality:
Anti–PD-1
Area of Research:
1L MGMT unmethylated GBM
Phase: 3
CC-90010 + chemo
Modality:
BET inhibitor
Area of Research:
Newly diagnosed glioblastoma
Phase: 1/2
Marizomib
Modality:
Proteasome inhibitor
Area of Research:
Newly diagnosed glioblastoma
Phase: 3
Pomalidomide
Modality:

IMiD® agent

Area of Research:
Pediatric glioblastoma
Phase: 2
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
Children or adolescents with high-grade primary CNS malignancies
Phase: 1/2
CC-90010
Modality:
BET inhibitor
Area of Research:
Progressive or recurrent WHO Grade II diffuse astrocytoma, Grade III anaplastic astrocytoma and recurrent glioblastoma
Phase: 1/2
Expand all Displaying 5 of 31

No results found. Try adjusting filters to view more results.

Gastrointestinal
Nivolumab
Modality:
Anti–PD-1
Area of Research:
Adjuvant esophageal or GEJ cancer
Phase: 3
Nivolumab
Modality:
Anti–PD-1
Area of Research:
Adjuvant HCC
Phase: 3
Nivolumab
Modality:
Anti–PD-1
Area of Research:
1L advanced HCC
Phase: 3
Nivolumab + ipilimumab
Modality:
Anti–PD-1 + anti–CTLA-4
Area of Research:
1L advanced HCC
Phase: 3
Nivolumab + ipilimumab or chemo
Modality:
Anti–PD-1 + anti–CTLA-4
Area of Research:
1L unresectable advanced, metastatic gastric, or GEJ cancer
Phase: 3
Nivolumab + ipilimumab or chemo
Modality:
Anti–PD-1 + anti–CTLA-4
Area of Research:
1L unresectable advanced, recurrent, or metastatic esophageal squamous cell cancer
Phase: 3
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
1L+ recurrent or metastatic MSI-H/dMMR CRC
Phase: 3
Nivolumab + TACE ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
Intermediate stage HCC
Phase: 3
Nivolumab + chemo + anti-VEGF
Modality:
Anti–PD-1 + anti-VEGF
Area of Research:
1L mCRC
Phase: 2/3
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
1L+ recurrent or metastatic MSI-H/dMMR CRC
Phase: 2
Nivolumab ± relatlimab
Modality:
Anti–PD-1 ± anti–LAG-3
Area of Research:
2L+ metastatic or advanced MSI-H/dMMR CRC
Phase: 2
Nivolumab + ipilimumab
Modality:
Anti–PD-1 + anti–CTLA-4
Area of Research:
2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase: 2
Nivolumab + relatlimab
Modality:
Anti–PD-1 + anti–LAG-3
Area of Research:
2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase: 2
Nivolumab + linrodostat mesylate
Modality:
Anti–PD-1 + IDO1 inhibitor
Area of Research:
2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase: 2
Nivolumab + PARP inhibitor
Modality:
Anti–PD-1 + PARP inhibitor
Area of Research:
2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase: 2
Ipilimumab + PARP inhibitor
Modality:
Anti–CTLA-4 + PARP inhibitor
Area of Research:
2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase: 2
Nivolumab + ipilimumab + PARP inhibitor
Modality:
Anti–PD-1 + anti–CTLA-4 + PARP inhibitor
Area of Research:
2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase: 2
Nivolumab + ipilimumab ± MEK inhibitor
Modality:
Anti–PD-1 + anti–CTLA-4 ± MEK inhibitor
Area of Research:
2L+ metastatic or advanced MSS CRC
Phase: 2
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
2L+ advanced or metastatic EC, GC, or GEJ carcinoma
Phase: 1/2
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
2L+ advanced or metastatic pancreatic cancer
Phase: 1/2
Nivolumab + ipilimumab + MEK inhibitor
Modality:
Anti–PD-1 + anti–CTLA-4 + MEK inhibitor
Area of Research:
2L+ advanced or metastatic pancreatic cancer
Phase: 1/2
Nivolumab + MEK inhibitor ± ipilimumab
Modality:
Anti–PD-1 + MEK inhibitor ±
anti–CTLA-4
Area of Research:
2L+ mCRC
Phase: 1/2
Nivolumab ± anti-CD38
Modality:
Anti–PD-1 ± anti-CD38
Area of Research:
Advanced or metastatic pancreatic cancer
Phase: 1/2
Expand all Displaying 5 of 31

No results found. Try adjusting filters to view more results.

Genitourinary
Nivolumab ± bempegaldesleukin (NKTR-214)
Modality:
Anti–PD-1 ± CD122-biased IL-2 receptor
Area of Research:
Peri-operative MIBC
Phase: 3
Nivolumab + chemo ± linrodostat mesylate
Modality:
Anti–PD-1 ± IDO1 inhibitor
Area of Research:
Peri-operative MIBC
Phase: 3
Nivolumab
Modality:
Anti–PD-1
Area of Research:
Adjuvant invasive high-risk urothelial carcinoma
Phase: 3
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
Adjuvant RCC
Phase: 3
Nivolumab + ipilimumab or chemo
Modality:
Anti–PD-1 + anti–CTLA-4
Area of Research:
1L unresectable or metastatic urothelial carcinoma
Phase: 3
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
1L advanced RCC
Phase: 3
Nivolumab + bempegaldesleukin (NKTR-214)
Modality:
Anti–PD-1 + CD122-preferential IL-2 pathway agonist
Area of Research:
1L advanced metastatic RCC
Phase: 3
Nivolumab + TKI ± ipilimumab
Modality:
Anti–PD-1 + TKI ± anti–CTLA-4
Area of Research:
1L advanced or metastatic RCC
Phase: 3
Nivolumab + TKI ± bempegaldesleukin (NKTR-214)
Modality:
Anti–PD-1 + TKI ± CD122-preferential IL-2 pathway agonist
Area of Research:
1L advanced metastatic RCC
Phase: 1/2
Nivolumab + chemo + steroid
Modality:
Anti–PD-1
Area of Research:
2L+ metastatic CRPC
Phase: 3
Ipilimumab ± nivolumab
Modality:
Anti–CTLA-4 ± anti–PD-1
Area of Research:
2L+ metastatic CRPC
Phase: 2
Nivolumab + BCG
Modality:
Anti–PD-1
Area of Research:
BCG relapsed or refractory high-risk NMIBC
Phase: 3
Nivolumab + BCG + linrodostat mesylate
Modality:
Anti–PD-1 + BCG + IDO1 inhibitor
Area of Research:
BCG relapsed or refractory high-risk NMIBC
Phase: 2
Nivolumab ± BCG
Modality:
Anti–PD-1 ± BCG
Area of Research:
BCG relapsed or refractory high-risk NMIBC
Phase: 2
Nivolumab + linrodostat mesylate ± BCG
Modality:
Anti–PD-1 + IDO1 inhibitor ± BCG
Area of Research:
BCG relapsed or refractory high-risk NMIBC
Phase: 2
Nivolumab + PARP inhibitor or chemo or
anti–androgen therapy
Modality:
Anti–PD-1 + PARP inhibitor
Area of Research:
Metastatic CRPC
Phase: 2
Expand all Displaying 5 of 31

No results found. Try adjusting filters to view more results.

Head & Neck
Nivolumab + ipilimumab
Modality:
Anti–PD-1 + anti–CTLA-4
Area of Research:
1L recurrent or metastatic SCCHN
Phase: 3
Motolimod
Modality:
TLR8 agonist
Area of Research:
SCCHN
Phase: 1

No results found. Try adjusting filters to view more results.

Lung
Nivolumab + chemo
Modality:
Anti–PD-1
Area of Research:
Resectable NSCLC (≥4 cm)
Phase: 3
Neoadjuvant nivolumab + chemo, followed by adjuvant nivolumab
Modality:
Anti–PD-1
Area of Research:
Resectable NSCLC (≥4 cm)
Phase: 3
Nivolumab + chemo + RT, followed by maintenance nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
Locally advanced NSCLC amenable to cCRT
Phase: 3
Nivolumab + ipilimumab
Modality:
Anti–PD-1 + anti–CTLA-4
Area of Research:
1L mNSCLC
Phase: 3
Nivolumab + ipilimumab
Modality:
Anti–PD-1 + anti–CTLA-4
Area of Research:
1L unresectable malignant pleural mesothelioma
Phase: 3
Nivolumab + ipilimumab
Modality:
Anti–PD-1 + anti–CTLA-4
Area of Research:
1L mNSCLC
Phase: 2
Nivolumab + ipilimumab or chemo
Modality:
Anti–PD-1 + anti–CTLA-4
Area of Research:
2L+ EGFR-mutation-positive NSCLC
Phase: 3
Nivolumab
Modality:
Anti–PD-1
Area of Research:
2L mNSCLC
Phase: 3
Nivolumab
Modality:
Anti–PD-1
Area of Research:
2L mNSCLC
Phase: 2
Anti-fucosyl GM1 ± nivolumab
Modality:
Anti-fucosyl GM1 ± anti–PD-1
Area of Research:
Relapsed or refractory SCLC
Phase: 1/2
CC-90011
Modality:
LSD1 inhibitor
Area of Research:
Extensive-stage SCLC
Phase: 1
ACY 241 + nivolumab
Modality:
HDAC6 inhibitor + anti–PD-1
Area of Research:
2L+ unresectable NSCLC
Phase: 1
Expand all Displaying 5 of 31

No results found. Try adjusting filters to view more results.

Melanoma
Nivolumab
Modality:
Anti–PD-1
Area of Research:
Adjuvant stage IIB/C melanoma
Phase: 3
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
Adjuvant fully resected melanoma
Phase: 3
Nivolumab ± bempegaldesleukin (NKTR-214)
Modality:
Anti–PD-1 ± CD122-preferential IL-2 pathway agonist
Area of Research:
Adjuvant fully resected melanoma in patients at high risk for recurrence
Phase: 3
Nivolumab ± relatlimab
Modality:
Anti–PD-1 ± anti–LAG-3
Area of Research:
1L unresectable or metastatic melanoma
Phase: 2/3
Nivolumab ± bempegaldesleukin (NKTR-214)
Modality:
Anti–PD-1 ± CD122-preferential IL-2 pathway agonist
Area of Research:
1L unresectable or metastatic melanoma
Phase: 3
Nivolumab ± ipilimumab
Modality:
Anti–PD-1 ± anti–CTLA-4
Area of Research:
Resectable stage III melanoma
Phase: 2
Nivolumab ± relatlimab
Modality:
Anti–PD-1 ± anti–LAG-3
Area of Research:
Advanced or unresectable melanoma patients who have progressed on/after anti–PD-(L)1 therapy
Phase: 1
Expand all Displaying 5 of 31

No results found. Try adjusting filters to view more results.

Probody is a trademark of CytomX Therapeutics, Inc.
IMiD® and CELMoD® are registered trademarks of Celgene Corporation.

=Trial investigates BMS agent(s) in combination with 1 or more non–BMS-owned assets. Development partnerships include:

  • Elotuzumab: AbbVie
  • Bempegaldesleukin: Nektar
  • Cabozantinib: Exelixis
  • GEMoaB CD3xPSCA, GEM333: GEMoaB Monoclonals GmbH
  • bb21217, ide-cel: bluebird bio
  • Luspatercept-aamt: Acceleron Pharma
  • Enasidenib, MAT2A: Agios Pharmaceuticals, Inc.
  • IK175: Ikena Oncology
  • Rucaparib: Clovis Oncology

 
*Trial investigates delivering nivolumab and/or ipilimumab subcutaneously.
Trial investigates more than 1 dosing or sequencing option.

1L=first line; 1L+=1L and above; 2L=second line; 2L+=2L and above; 3L=third line; 3L+=3L and above; 4L=fourth line; 4L+=4L and above; ADC=antibody-drug conjugate; ADP=adenosine diphosphate; AHR=aryl hydrocarbon receptor; AML=acute myeloid leukemia; BCG=bacillus Calmette-Guérin; BCMA=B-cell maturation antigen; BCR-ABL=breakpoint cluster region-Abelson; BET=bromodomain and extraterminal domain; BRD4=bromodomain containing 4; CAR T=chimeric antigen receptor T cells; CCR2/5=chemokine (C-C motif) receptors 2/5; cCRT=concurrect chemoradiotherapy; CDK=cyclin-dependent kinase; chemo=chemotherapy; CML=chronic myeloid leukemia; CNS=central nervous system; CRC=colorectal cancer; CRPC=castration-resistant prostate cancer; CTLA-4=cytotoxic T-lymphocyte antigen 4; CTLA-4-NF=CTLA-4 non-fucosyl; dMMR=mismatch repair deficient; EC=esphogeal cancer; EGFR=epidermal growth factor receptor; EP4=prostaglandin E2 receptor 4; ER=estrogen receptor; GBM=glioblastoma multiforme; GC=gastric cancer; GEJ=gastroesophageal junction; HCC=hepatocellular carcinoma; HER2=human epidermal growth factor receptor 2; IDH2=isocitrate dehydrogenase-2; IDO1=indoleamine 2,3-dioxygenase-1; Ig=immunoglobulin; IL-2=interleukin-2; IL-8=interleukin-8; IMiD=immunomodulatory drug; ITIM=immunoreceptor tyrosine-based inhibitory motif; JAK2=Janus kinase 2; LAG-3=lymphocyte-activation gene 3; LSD1=lysine-specific histone demethylase 1A; mCRC=metastatic CRC; MEK=mitogen-activated protein kinase; MGMT=O6-methylguanine-DNA methyltransferase; MIBC=muscle-invasive bladder cancer; mNSCLC=metastatic NSCLC; MSI-H=microsatellite instability-high; MSS=microsatellite stable; NHL=non-Hodgkin lymphoma; NK=natural killer; NLRP3=nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3; NMIBC=non–muscle-invasive bladder cancer; NSCLC=non–small cell lung cancer; PARP=poly (ADP-ribose) polymerase; PD-1=programmed death receptor-1; PSCA=prostate stem cell antigen; RCC=renal cell carcinoma; R/R=relapsed/refractory; RT=radiotherapy; SCCHN=squamous cell carcinoma of the head and neck; SCLC=small cell lung cancer; SIRPα=CD47-signal regulatory protein alpha; SLAMF7=signaling lymphocytic activation molecule family member 7; STING=stimulator of interferon genes; TACE=transarterial chemoembolization; TIGIT=T-cell immunoreceptor with Ig and ITIM domains; TIM-3=T-cell immunoglobulin mucin-3; TKI=tyrosine kinase inhibitor; TLR8=Toll-like receptor 8; TMB-H=tumor mutational burden high; TNBC=triple-negative breast cancer; VEGF=vascular endothelial growth factor.

Filter by Therapeutic Area and Phase Clear All
Hematologic Malignancies
Relatlimab
Modality:
Anti–LAG-3
Area of Research:
Hematologic malignancies
Phase: 1
Nivolumab
Modality:
Anti–PD-1
Area of Research:
Hematologic malignancies
Phase: 1
Modality:
BET (BRD4) small-molecule inhibitor
Area of Research:
Hematologic malignancies
Phase: 1/2
Azacitidine (CC-486)
Modality:
Oral HMA
Area of Research:
Hematologic malignancies
Phase: 2

No results found. Try adjusting filters to view more results.

Multiple Myeloma
ide-cel*
Modality:
Anti-BCMA CAR T cells
Area of Research:
3L–5L R/R multiple myeloma
Phase: 3
ide-cel*
Modality:
Anti-BCMA CAR T cells
Area of Research:
2L R/R multiple myeloma
Phase: 2
ide-cel*
Modality:
Anti-BCMA CAR T cells
Area of Research:
4L+ R/R multiple myeloma
Phase: 2
ide-cel*
Modality:
Anti-BCMA CAR T cells
Area of Research:
High-risk newly diagnosed multiple myeloma
Phase: 1
Elotuzumab + lenalidomide + steroid
Modality:
Anti-SLAMF7 + IMiD® agent + steroid
Area of Research:
1L multiple myeloma
Phase: 3
Iberdomide
Modality:
Cereblon/E3 ligase modulator
Area of Research:
R/R multiple myeloma
Phase: 1/2
CC-99712
Modality:
Anti-BCMA antibody-drug conjugate
Area of Research:
R/R multiple myeloma
Phase: 1
orva-cel
Modality:
Anti-BCMA CAR T cells
Area of Research:
4L+ R/R multiple myeloma
Phase: 2
bb21217*
Modality:
Anti-BCMA CAR T cells
Area of Research:
R/R multiple myeloma
Phase: 1
CC-93269
Modality:
Anti-BCMA T-cell engager
Area of Research:
R/R multiple myeloma
Phase: 1
CC-92480
Modality:
Cereblon/E3 ligase modulator
Area of Research:
4L+ R/R multiple myeloma
Phase: 1
CC-98633
Modality:
BCMA NEX T
Area of Research:
R/R multiple myeloma
Phase: 1
Nivolumab + anti-CD38
Modality:
Anti–PD-1 + anti-CD38
Area of Research:
3L+ R/R multiple myeloma
Phase: 1/2
Expand all Displaying 5 of 31

No results found. Try adjusting filters to view more results.

Myelodysplastic Syndromes
Luspatercept-aamt
Modality:
Erythroid maturation agent
Area of Research:
ESA naïve
Phase: 3
Azacitidine (CC-486)
Modality:
Oral HMA
Area of Research:
Lower risk
Phase: 3
Azacitidine (CC-486)
Modality:
Oral HMA
Area of Research:
Post-HMA failure
Phase: 2

No results found. Try adjusting filters to view more results.

Acute Myeloid Leukemia
Enasidenib
Modality:
IDH2 inhibitor
Area of Research:
R/R AML with an IDH2 mutation
Phase: 3
Enasidenib
Modality:
IDH2 inhibitor
Area of Research:
1L AML with an IDH2 mutation
Phase: 2
Azacitidine (CC-486)
Modality:
Oral HMA
Area of Research:
Post-induction AML maintenance
Phase: 3
CD3xCD33 Bispecific (GEMoaB)
Modality:
CD3xCD33 bispecific antibody
Area of Research:
R/R AML
Phase: 1
CC-90009
Modality:
Cereblon/E3 ligase modulator
Area of Research:
R/R AML
Phase: 1

No results found. Try adjusting filters to view more results.

Lymphoma/CLL
Romidepsin
Modality:
Histone deacetylase inhibitor
Area of Research:
1L peripheral T-cell lymphoma
Phase: 3
liso-cel
Modality:
Anti-CD19 CAR T cells
Area of Research:
2L R/R aggressive large B-cell lymphoma
Phase: 3
liso-cel
Modality:
Anti-CD19 CAR T cells
Area of Research:
3L+ diffuse large B-cell lymphoma
Phase: 2
liso-cel
Modality:
Anti-CD19 CAR T cells
Area of Research:
2L diffuse large B-cell lymphoma
Phase: 2
liso-cel
Modality:
Anti-CD19 CAR T cells
Area of Research:
3L+ chronic lymphocytic leukemia or small lymphocytic lymphoma
Phase: 1/2
liso-cel
Modality:
Anti-CD19 CAR T cells
Area of Research:
2L+ follicular lymphoma/3L+ marginal zone lymphoma
Phase: 2
liso-cel
Modality:
Anti-CD19 CAR T cells
Area of Research:
2L+ pediatric B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
Phase: 1/2
liso-cel
Modality:
Anti-CD19 CAR T cells
Area of Research:
3L+ mantle cell lymphoma
Phase: 1
liso-cel
Modality:
Anti-CD19 CAR T cells
Area of Research:
2L primary CNS lymphoma
Phase: 2
Nivolumab + anti-CD30 (ADC)
Modality:
Anti–PD-1 + anti-CD30 (ADC)
Area of Research:
2L+ R/R advanced classical Hodgkin lymphoma
Phase: 3
Nivolumab + anti-CD30 (ADC)
Modality:
Anti–PD-1 + anti-CD30 (ADC)
Area of Research:
Children, adolescents, and young adults with 2L classical Hodgkin lymphoma
Phase: 2
Nivolumab
Modality:
Anti–PD-1
Area of Research:
2L+ R/R primary CNS lymphoma or primary testicular lymphoma
Phase: 2
Nivolumab
Modality:
Anti–PD-1
Area of Research:
2L classical Hodgkin lymphoma
Phase: 2
Nivolumab + chemo
Modality:
Anti–PD-1
Area of Research:
1L classical Hodgkin lymphoma
Phase: 2
Nivolumab + anti-CD30 (ADC)
Modality:
Anti–PD-1 + anti-CD30 (ADC)
Area of Research:
2L+ R/R non-Hodgkin lymphoma
Phase: 1/2
Azacitidine (CC-486)
Modality:
Oral HMA
Area of Research:
Angioimmunoblastic T-cell lymphoma
Phase: 3
CC-90010
Modality:
BET inhibitor
Area of Research:
Non-Hodgkin lymphoma
Phase: 1
CC-95775
Modality:
BET inhibitor
Area of Research:
Non-Hodgkin lymphoma
Phase: 1
CC-99282
Modality:
Cereblon/E3 ligase modulator
Area of Research:
R/R non-Hodgkin lymphoma
Phase: 1
CC-95251
Modality:
Anti-SIRPα antibody
Area of Research:
Non-Hodgkin lymphoma
Phase: 1
CC-90011
Modality:
LSD1 inhibitor
Area of Research:
R/R non-Hodgkin lymphoma
Phase: 1
AG-270
Modality:
MAT2A inhibitor
Area of Research:
Lymphoma
Phase: 1
Dasatinib
Modality:
BCR-ABL TKI
Area of Research:
1L/2L+ chronic phase CML
Phase: 2
Iberdomide
Modality:
Cereblon/E3 ligase modulator
Area of Research:
Non-Hodgkin lymphoma
Phase: 1
CC-97540
Modality:
CD19 NEX T
Area of Research:
R/R non-Hodgkin lymphoma
Phase: 1
TRPH-222
Modality:
CD22 ADC (TriPhase)
Area of Research:
R/R lymphoma
Phase: 1
Expand all Displaying 5 of 31

No results found. Try adjusting filters to view more results.

Beta-thalassemia
Luspatercept-aamt
Modality:
Erythroid maturation agent
Area of Research:
Non-transfusion–dependent beta-thalassemia
Phase: 2

No results found. Try adjusting filters to view more results.

Myelofibrosis
Fedratinib
Modality:
JAK2 inhibitor
Area of Research:
Myelofibrosis previously treated with ruxolitinib
Phase: 3
Luspatercept-aamt
Modality:
Erythroid maturation agent
Area of Research:
Myelofibrosis anemia
Phase: 2

No results found. Try adjusting filters to view more results.

=Trial investigates BMS agent(s) in combination with 1 or more non–BMS-owned assets. Development partnerships include:

  • Elotuzumab: AbbVie
  • Bempegaldesleukin: Nektar
  • Cabozantinib: Exelixis
  • GEMoaB CD3xPSCA, GEM333: GeMoaB Monoclonals GmbH
  • Luspatercept-aamt: Acceleron Pharma
  • Enasidenib, MAT2A: Agios Pharmaceuticals, Inc.
  • AHR: Ikena Oncology

*Celgene in collaboration with bluebird bioTM.
Developed by Juno Therapeutics, a Bristol-Myers Squibb Company.
Development partnership with Triphase Accelerator.

IMiD® is a registered trademark of Celgene Corporation.

1L=first line; 1L+=1L and above; 2L=second line; 2L+=2L and above; 3L=third line; 3L+=3L and above; 4L=fourth line; 4L+=4L and above; ADC=antibody drug conjugate; AML=acute myeloid leukemia; BCMA=B-cell maturation antigen; BCR-ABL=breakpoint cluster region-Abelson; BET=bromodomain and extraterminal domain; BRD4=bromodomain containing 4; CAR T=chimeric antigen receptor T cells; chemo=chemotherapy; CML=chronic myeloid leukemia; CNS=central nervous system; CTLA-4=cytotoxic T-lymphocyte antigen 4; DNA=deoxyribonucleic acid; ESA=erythoropoiesis-stimulating agent; HMA=hypomethylating agent; ide-cel=idecabtagene vicleucel; IDH2=isocitrate dehydrogenase-2; IMiD=immunomodulatory drug; JAK2=Janus kinase 2; LAG-3=lymphocyte-activation gene 3; liso-cel=lisocabtagene maraleucel; LSD1=lysine-specific histone demethylase 1A; MM=multiple myeloma; NEX T=next-generation CAR-T candidates; NHL=non-Hodgkin lymphoma; orva-cel=orvacabtagene autoleucel; PD-1=programmed death receptor-1; R/R=relapsed/refractory; SIRPα=CD47-signal regulatory protein alpha; SLAMF7=signaling lymphocytic activation molecule family member 7; TKI=tyrosine kinase inhibitor.